SI-BONE To Report Third Quarter 2021 Financial Results on November 8, 2021

Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN), a leader in medical technology for musculoskeletal disorders, will release its Q3 2021 financial results on November 8, 2021, after market close. A conference call to discuss these results will begin at 1:30 p.m. PT. Interested investors can join by dialing (866) 470-1968 domestically or (409) 217-8248 internationally, with conference ID: 4991983. Additionally, a live webcast will be available on the company’s website and archived for 90 days.

SI-BONE is well-regarded for its iFuse Implant System, used in over 60,000 procedures.

SANTA CLARA, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2021 after market close on Monday, November 8, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (866) 470-1968 for domestic callers or (409) 217-8248 for international callers, using conference ID: 4991983. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. In 2009, SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, shown to be a source of pain in 15% to 30% of chronic low back pain. Since then, more than 2,500 surgeons have performed a combined total of more than 60,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two RCT’s and over 100 peer reviewed publications, has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System. SI-BONE is leveraging its market leadership position, supported by this proprietary reimbursement advantage, to commercialize other devices intended for surgical treatment of related aspects of the human anatomy. For more information or to join our team, please visit us at www.si-bone.com.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved.

Investor Contact:

Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:
Joe Powers
jpowers@si-bone.com

FAQ

When will SI-BONE report its Q3 2021 financial results?

SI-BONE will report its Q3 2021 financial results on November 8, 2021, after market close.

What time is the SI-BONE Q3 2021 conference call?

The conference call will start at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

How can I listen to the SI-BONE Q3 2021 conference call?

You can listen to the conference call by dialing (866) 470-1968 for domestic calls or (409) 217-8248 for international calls, using conference ID: 4991983.

Where can I find the webcast for the SI-BONE Q3 2021 results?

The live audio of the webcast will be available on the 'Investors' section of SI-BONE's website.

What is the significance of the iFuse Implant System in SI-BONE's operations?

The iFuse Implant System is a key product for SI-BONE, used in over 60,000 procedures for minimally invasive surgery of the SI joint.